Skip to content

EBIT at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
-$4.62M-124%
LBR
LB Pharmaceuticals Inc Common StockLBRX
-$19.05M-259%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Johnson & Johnson logo
Johnson & JohnsonJNJ
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.39B+100%
Enterprise value$1.34B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Calculated from MapLight Therapeutics, Inc. ’s reported figures.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's EBIT?
MapLight Therapeutics, Inc. (MPLT) reported EBIT of -$64.5M in Q1 2026.
How has MapLight Therapeutics, Inc. 's EBIT changed year-over-year?
MapLight Therapeutics, Inc. 's EBIT decreased by 174.0% year-over-year, from -$23.54M to -$64.5M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.